The Ritedose Corporation
The Ritedose Corporation (TRC) offers outsourced development and manufacturing services for ophthalmology drugs, respiratory drugs, and vaccines. TRC also develops and markets its own portfolio of generic drugs with a particular focus on critical medicines in short supply.
Investment rationale
US market leader in the attractive blow-fill-seal CDMO market, boasting more than 1.5x the capacity of its nearest competitor and a tenured, blue-ship customer base. Attractive business model with a double-digit annual growth in organic sales since 2007 and high cash conversion.
Year of investment
2021
